ALLO vs EDIT: stock comparison and AI forecast
Allogene Therapeutics, Inc. (ALLO) and Editas Medicine, Inc. (EDIT) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ALLO Allogene Therapeutics, Inc.
- Price
- $1.12 -48.4% · 6M
- Market Cap
- $387M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
EDIT Editas Medicine, Inc.
- Price
- $2.60 -14.5% · 6M
- Market Cap
- $399M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- ALLO and EDIT have similar market capitalizations ($387M and $399M).
- Over the last six months EDIT returned -14.5% and ALLO -48.4%.
- EDIT carries 1.25 times debt per unit of equity, against 0.26 times for ALLO.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ALLO | EDIT |
|---|---|---|
| Market Cap | $387M | $399M |
| P/B Ratio | 0.89x | 3.79x |
| EPS | $-0.77 | $-1.32 |
| Book Value/Share | $1.26 | $0.69 |
| Revenue/Share | – | $0.29 |
| FCF/Share | $-0.30 | $-0.78 |
Profitability & Margins
| Metric | ALLO | EDIT |
|---|---|---|
| ROE | -37.9% | – |
| ROA | -30.1% | – |
| ROIC | -34.8% | -44.9% |
| Operating Margin | -3886.1% | -171.7% |
| Net Margin | -3566.7% | – |
| EBT Margin | -3489.0% | -171.7% |
Financial Health
| Metric | ALLO | EDIT |
|---|---|---|
| Current Ratio | 10.72x | 3.19x |
| D/E Ratio | 0.26x | 1.25x |
| Financial Leverage | 1.26x | 2.25x |
| Interest Coverage | -6.6x | -17.5x |
| Working Capital | $308M | $150M |
Cash Flow
| Metric | ALLO | EDIT |
|---|---|---|
| Operating Cash Flow | -$102M | -$120M |
| Free Cash Flow | -$103M | -$121M |
| Capital Spending | -$400K | -$690K |
| FCF/Sales | – | -272.9% |
| CapEx/Sales | – | 1.6% |
Operational Efficiency
| Metric | ALLO | EDIT |
|---|---|---|
| Asset Turnover | – | 0.19x |
| Receivables Turnover | – | 16.2x |
| Fixed Assets Turnover | – | 17.2x |
| Days Sales Outstanding | – | 23 days |
Income Statement
| Metric | ALLO | EDIT |
|---|---|---|
| Total Revenue | – | $44M |
| Operating Income | -$180M | -$76M |
| Net Income | -$165M | – |
| R&D Expense | $123M | $85M |
Dividend & Shareholder Information
| Metric | ALLO | EDIT |
|---|---|---|
| Shares Outstanding | 345M | 154M |
ALLO vs EDIT: stock comparison and AI forecast
Which is bigger, ALLO or EDIT?
ALLO and EDIT have similar market capitalizations ($387M and $399M).
Which stock performed better over the last six months, ALLO or EDIT?
Over the last six months EDIT returned -14.5% and ALLO -48.4%.
Which one does Intratio's AI model rank higher, ALLO or EDIT?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.